Tonix Pharmaceuticals (NASDAQ:TNXP) Shares Down 0.4% - Should You Sell?

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP - Get Free Report) traded down 0.4% during trading on Tuesday . The stock traded as low as $28.85 and last traded at $30.40. 844,399 shares changed hands during mid-day trading, an increase of 23% from the average session volume of 685,221 shares. The stock had previously closed at $30.51.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on TNXP shares. Noble Financial reiterated an "outperform" rating and set a $70.00 price target on shares of Tonix Pharmaceuticals in a report on Thursday, March 20th. StockNews.com assumed coverage on shares of Tonix Pharmaceuticals in a research note on Monday, February 10th. They set a "sell" rating for the company.

Tonix Pharmaceuticals Price Performance

The company has a market cap of $37.70 million, a P/E ratio of 0.00 and a beta of 2.23. The stock has a 50-day simple moving average of $18.79 and a 200 day simple moving average of $20.13. The company has a debt-to-equity ratio of 0.07, a quick ratio of 2.81 and a current ratio of 3.33.

Tonix Pharmaceuticals (NASDAQ:TNXP - Get Free Report) last issued its earnings results on Tuesday, March 18th. The company reported ($9.77) EPS for the quarter, missing the consensus estimate of ($6.23) by ($3.54). The firm had revenue of $2.58 million during the quarter, compared to the consensus estimate of $3.20 million. Tonix Pharmaceuticals had a negative return on equity of 163.95% and a negative net margin of 1,197.86%. On average, equities analysts expect that Tonix Pharmaceuticals Holding Corp. will post -1762.5 EPS for the current year.

Remove Ads

Institutional Trading of Tonix Pharmaceuticals

Several institutional investors have recently bought and sold shares of the stock. Two Sigma Investments LP bought a new position in shares of Tonix Pharmaceuticals during the fourth quarter valued at $66,000. Point72 Asset Management L.P. bought a new stake in Tonix Pharmaceuticals during the 4th quarter worth approximately $526,000. Jane Street Group LLC increased its holdings in Tonix Pharmaceuticals by 5,932.3% during the 4th quarter. Jane Street Group LLC now owns 1,662,682 shares of the company's stock valued at $548,000 after purchasing an additional 1,635,119 shares in the last quarter. Northern Trust Corp bought a new stake in shares of Tonix Pharmaceuticals during the fourth quarter worth $162,000. Finally, Geode Capital Management LLC increased its stake in shares of Tonix Pharmaceuticals by 1,600.1% in the fourth quarter. Geode Capital Management LLC now owns 1,971,894 shares of the company's stock valued at $650,000 after buying an additional 1,855,907 shares in the last quarter. Institutional investors and hedge funds own 82.26% of the company's stock.

About Tonix Pharmaceuticals

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.